Bioamber Inc (NYSE:BIOA)’s share price hit a new 52-week low during trading on Friday . The company traded as low as $0.49 and last traded at $0.49, with a volume of 645,067 shares traded. The stock had previously closed at $0.53.

A number of equities analysts have recently commented on BIOA shares. ValuEngine raised Bioamber from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Zacks Investment Research downgraded Bioamber from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company set a $3.00 price objective on Bioamber and gave the stock a “hold” rating in a research report on Monday, July 17th.

The company’s market capitalization is $18.11 million. The company has a 50-day moving average price of $2.22 and a 200 day moving average price of $2.62.

Bioamber (NYSE:BIOA) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. Bioamber had a negative return on equity of 42.70% and a negative net margin of 216.06%. The business had revenue of $4.12 million for the quarter, compared to analysts’ expectations of $4.09 million. On average, analysts predict that Bioamber Inc will post ($0.48) EPS for the current year.

A number of large investors have recently bought and sold shares of BIOA. Bank of New York Mellon Corp increased its stake in Bioamber by 336.2% in the second quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares in the last quarter. TD Asset Management Inc. acquired a new stake in Bioamber during the second quarter valued at about $977,000. Robecosam AG increased its stake in Bioamber by 3.1% in the first quarter. Robecosam AG now owns 825,000 shares of the biotechnology company’s stock valued at $1,898,000 after buying an additional 25,000 shares in the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in Bioamber during the first quarter valued at about $2,548,000. Finally, FMR LLC increased its stake in Bioamber by 18.7% in the first quarter. FMR LLC now owns 1,335,000 shares of the biotechnology company’s stock valued at $3,097,000 after buying an additional 210,000 shares in the last quarter. Institutional investors own 46.96% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/bioamber-inc-bioa-sets-new-12-month-low-at-0-49/1473419.html.

About Bioamber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.